1. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
by Henk M. Lokhorst, Bronno van der Holt, Jan J. Cornelissen, Marie-José Kersten, Marinus van Oers, Reinier Raymakers, Monique C. Minnema, Sonja Zweegman, Jeroen J. Janssen, Mark Zijlmans, Gerard Bos, Nicolaas Schaap, Shulamiet Wittebol, Okke de Weerdt, Rianne Ammerlaan, and Pieter Sonneveld
Blood
Volume 119(26):
June 28, 2012
©2012 by American Society of Hematology

2. Design of the study and patient flow.
Henk M. Lokhorst et al. Blood 2012;119:
©2012 by American Society of Hematology

3. Kaplan-Meier survival curves of 260 myeloma patients included in the HOVON-50 study by donor availability.
Kaplan-Meier survival curves of 260 myeloma patients included in the HOVON-50 study by donor availability. Actuarial rates of PFS (A) and OS (B) according to availability of an HLA-identical sibling, that is, donor versus no-donor. PFS and OS are presented as from the date of autologous SCT.
Henk M. Lokhorst et al. Blood 2012;119:
©2012 by American Society of Hematology

4. Cumulative incidence of relapse.
Cumulative incidence of relapse. Cumulative incidence of relapse at 6 years was 77% in the no-donor arm versus 55% in the donor arm.
Henk M. Lokhorst et al. Blood 2012;119:
©2012 by American Society of Hematology

5. Nonrelapse mortality.
Nonrelapse mortality. NRM for patients having or not having a donor included in the HOVON-50 study.
Henk M. Lokhorst et al. Blood 2012;119:
©2012 by American Society of Hematology

6. Kaplan-Meier survival curves of 214 myeloma patients included in the HOVON-50/54 studies by treatment according to protocol initiated after auto-SCT.
Kaplan-Meier survival curves of 214 myeloma patients included in the HOVON-50/54 studies by treatment according to protocol initiated after auto-SCT. Actuarial rates of PFS2 (A) and OS2 (B) according to treatment started after auto-SCT, ie, allo-RIC versus maintenance with thalidomide or α-interferon (including 3 patients who received a second HDM-200). PFS2 and OS2 are presented as from the date of allo-RIC or second HDM, or start maintenance, whichever applicable.
Henk M. Lokhorst et al. Blood 2012;119:
©2012 by American Society of Hematology